Oculo-respiratory syndrome following influenza vaccination:: evidence for occurrence with more than one influenza vaccine

被引：17

作者：

De Serres, G

Boulianne, N

Duval, B

Rochette, L

Grenier, JL

Roussel, R

Donaldson, D

Tremblay, M

Toth, E

Ménard, S

Landry, M

Robert, Y

机构：

[1] Direct Sante Publ Quebec, Quebec City, PQ G1E 7G9, Canada

[2] Inst Natl Sante Publ Quebec, Quebec City, PQ G1E 7G9, Canada

[3] Direct Sante Publ Laurentides, St Jerome, PQ, Canada

[4] Direct Sante Publ Bas St Laurent, Riviere Du Loup, PQ G1E 7G9, Canada

[5] Direct Sante Publ Mauricie, Trois Rivieres, PQ G1E 7G9, Canada

[6] Ctr Quebec, Trois Rivieres, PQ G1E 7G9, Canada

[7] Direct Sante Publ Montreal, Montreal, PQ G1E 7G9, Canada

[8] Direct Sante Publ Estrie, Sherbrooke, PQ G1E 7G9, Canada

[9] Ministere Sante & Serv Sociaux Quebec, Quebec City, PQ G1E 7G9, Canada

来源：

VACCINE | 2003年 / 21卷 / 19-20期

关键词：

oculo-respiratory syndrome; influenza vaccine; vaccine safety; adverse event;

D O I：

10.1016/S0264-410X(03)00095-1

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

We assessed the occurrence of oculo-respiratory syndrome (ORS) following two influenza vaccines: Fluviral(R) (Shire Biologics) or Vaxigrip(R) (Aventis Pasteur). ORS was identified amongst 5.3 and 4.6% of recipients, respectively (P = 0.54). With both vaccines, the risk of ORS was much greater in individuals who had ORS the previous year (2000) than in those without such history. In multivariate analysis, the odds ratio for ORS for patients with a prior history of ORS varied between 9.4 and 9.6 (P < 0.001) whereas that comparing Fluviral(R) and Vaxigrip(R) varied between 1.5 and 1.9 (P = 0.02-0.05). ORS is an adverse event that is present with more than one vaccine and may be present with any influenza vaccines to a greater or lesser degree. (C) 2003 Elsevier Science Ltd. All rights reserved.

引用

页码：2346 / 2353

页数：8

共 12 条

[1] Boulianne N, 2001, Can Commun Dis Rep, V27, P85
[2] *BUR INF DIS CTR I, 2000, CAN COMMUN DIS REP, V26, P201
[3] DESERRES G, 2003, VACCINE, V21, P2362
[4] DESERRES G, 2002, 9 C MAL INF QUEB CIT
[5] GRENIER JL, 2002, P 5 CAN NAT IMM C VI
[6] KING A, 2001, CAN COMMUN DIS REP, V27, P1
[7] National Advisory Committee on Immunization (NACI), 2001, Can Commun Dis Rep, V27, P1
[8] ORR P, 2001, CAN COM DIS REP, V27, P1
[9] Skowronski DA, 2002, CAN MED ASSOC J, V167, P853
[10] SKOWRONSKI DM, IN PRESS CLIN INFECT

← 1 2 →